Neuromyelitis Optica Spectrum Disorder Global Market Report 2025

Global Neuromyelitis Optica Spectrum Disorder Market Report 2025

Neuromyelitis Optica Spectrum Disorder Global Market Report 2025 - By Type (Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies), By Diagnosis (Imaging Tests, Magnetic Resonance Imaging (MRI), Blood Tests, Others Diagnosis), By Treatment Type (C5 Protein Inhibitor, Monoclonal Antibodies, Plasma Exchange Therapy, Corticosteroids, Immunoglobulin Therapy, Medication, Other Treatment Types), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By End-User (Hospitals, Specialty Clinics, Homecare, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Name: Neuromyelitis Optica Spectrum Disorder Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Neuromyelitis Optica Spectrum Disorder Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : April 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Neuromyelitis Optica Spectrum Disorder Global Market Report 2025

Proud Members Of

What Is Covered Under Neuromyelitis Optica Spectrum Disorder Market?

Neuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease that affects the central nervous system, primarily targeting the spinal cord and optic nerves. It is characterized by severe inflammation and demyelination (damage to the protective covering of nerve fibers) in these areas, leading to symptoms such as vision loss, paralysis, and loss of sensory function.

The main types of neuromyelitis optica spectrum disorder are neuromyelitis optica spectrum disorder with aquaporin-4 antibodies and neuromyelitis optica spectrum disorder without aquaporin-4 antibodies. Neuromyelitis optica spectrum disorder with aquaporin-4 antibodies occurs when the immune system attacks nerve fibers, causing inflammation, vision loss, and paralysis. It is diagnosed by several diagnoses, such as imaging tests, magnetic resonance imaging (MRI), blood tests, and others, and it is treated with several treatment types, including C5 protein inhibitors, monoclonal antibodies, plasma exchange therapy, corticosteroids, immunoglobulin therapy, medication, and others. It is distributed through various distribution channels such as hospital pharmacy, retail pharmacy, and online pharmacy and is used by several end-users, including hospitals, specialty clinics, home care, and others.

Neuromyelitis Optica Spectrum Disorder Market Size and growth rate 2025 to 2029: Graph

What Is The Neuromyelitis Optica Spectrum Disorder Market Size 2025 And Growth Rate?

The neuromyelitis optica spectrum disorder market size has grown strongly in recent years. It will grow from $2.35 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the increasing prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD), rising awareness and early diagnosis, rising therapeutic options and FDA approvals, growing research and development activities, and rising clinical trials for novel therapies.

What Is The Neuromyelitis Optica Spectrum Disorder Market Growth Forecast?

The neuromyelitis optica spectrum disorder market size is expected to see strong growth in the next few years. It will grow to $3.52 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising awareness and early diagnosis, increasing healthcare expenditure, rising investments in research and development, increasing prevalence of autoimmune diseases, increasing clinical trials for NMOSD therapies, and growing demand for personalized medicine. Major trends in the forecast period include advancements in precision medicine, collaboration & partnerships, technological innovations, integration of AI & big data in research, and a shift towards home-based treatments.

Book your 30 minutes free consultation with our research experts

How Is The Neuromyelitis Optica Spectrum Disorder Market Segmented?

The neuromyelitis optica spectrum disorder market covered in this report is segmented –

1) By Type: Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies

2) By Diagnosis: Imaging Tests, Magnetic Resonance Imaging (MRI), Blood Tests, Others Diagnosis

3) By Treatment Type: C5 Protein Inhibitor, Monoclonal Antibodies, Plasma Exchange Therapy, Corticosteroids, Immunoglobulin Therapy, Medication, Other Treatment Types

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP4) Antibodies: Relapsing NMOSD with AQP4-IgG, Monophasic NMOSD with AQP4-IgG, Severe Optic Neuritis with AQP4-IgG, Longitudinally Extensive Transverse Myelitis (LETM) with AQP4-IgG

2) By Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP4) Antibodies: NMOSD with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG), Seronegative NMOSD, Idiopathic NMOSD Cases, NMOSD Associated With Other Autoimmune Disorders

What Is Driving The Neuromyelitis Optica Spectrum Disorder Market? Rising Multiple Sclerosis Cases Fueling The Growth Of The Market Due To Improved Diagnostics And Increased Awareness

The increasing prevalence of multiple sclerosis is expected to propel the growth of the neuromyelitis optica spectrum disorder market going forward. Multiple sclerosis is a chronic autoimmune disease affecting the central nervous system, causing inflammation, nerve damage, and neurological symptoms. The increasing prevalence of multiple sclerosis is due to improvising diagnostic techniques, environmental influences, and genetic predisposition. Advancements in medical imaging, such as MRI, have allowed for earlier and more accurate diagnoses, leading to an apparent rise in cases. As more individuals are diagnosed with MS, there is a heightened awareness of neurological autoimmune diseases, leading to improved diagnostic methods and greater recognition of neuromyelitis optica spectrum disorder. For instance, in May 2024, according to the Multiple Sclerosis Trust, a UK-based national charity, the UK sees approximately 7,100 new multiple sclerosis cases annually, and some 135 persons are diagnosed with MS each week. Therefore, the increasing prevalence of multiple sclerosis drives the growth of the neuromyelitis optica spectrum disorder market.

Who Are The Major Players In The Global Neuromyelitis Optica Spectrum Disorder Market?

Major companies operating in the neuromyelitis optica spectrum disorder market are F. Hoffmann-La Roche Ltd., AstraZeneca, Merck KGaA, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd., Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc., Oregon Health & Science University, Arup Laboratories, Argenx SE, TG Therapeutics Inc., RemeGen Co. Ltd., Metropolis Healthcare, IASO Biotherapeutics, Harbour BioMed, Rush University Medical Center, Bio-Thera Solutions Ltd., Mitsubishi Tanabe Pharma Corporation, Viela Bio, Opexa Therapeutics

What Are The Key Trends Of The Global Neuromyelitis Optica Spectrum Disorder Market? Advancements In Complement Inhibition Transform NMOSD Treatment Landscape

Major companies operating in the neuromyelitis optica spectrum disorder market are focusing on developing innovative products, such as long-acting complement inhibitors, to enhance treatment efficacy and improve patient outcomes. Long-acting complement inhibitors are treatments that suppress the complement system for an extended duration, preventing inflammation and nerve damage in neuromyelitis optica spectrum disorder (NMOSD). They help minimize relapses and support long-term disease control. For instance, in March 2024, Alexion Pharmaceuticals, a US-based biopharmaceutical company, and AstraZeneca, a UK-based pharmaceutical industry, received approval for ULTOMIRIS (ravulizumab-cwvz) for the treatment of adults with anti-aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD). This approval marks Ultomiris as the first and only long-acting C5 complement inhibitor available for NMOSD treatment. The decision was based on the Phase III CHAMPION-NMOSD trial, where Ultomiris demonstrated a 98.6% reduction in relapse risk over 73 weeks compared to a placebo. Trial participants experienced no relapses, and no new safety concerns were identified.

What Are Latest Mergers And Acquisitions In The Neuromyelitis Optica Spectrum Disorder Market? Amgen Acquired Horizon Therapeutics To Expand Rare And Autoimmune Disease Portfolio

In October 2023, Amgen, a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. With this acquisition, Amgen expands its portfolio in the rare disease and autoimmune disease market, strengthening its position with first-in-class treatments such as UPLIZNA (ibalizumab-con) for neuromyelitis optica spectrum disorder (NMOSD) for adult patients who are anti-aquaporin-4 (AQP4) antibody positive. Horizon Therapeutics plc is an Ireland-based biotechnology company that provides treatment of neuromyelitis optica spectrum disorder.

What Is The Regional Outlook For The Global Neuromyelitis Optica Spectrum Disorder Market?

North America was the largest region in the neuromyelitis optica spectrum disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuromyelitis optica spectrum disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neuromyelitis optica spectrum disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuromyelitis Optica Spectrum Disorder Market?

The neuromyelitis optica spectrum disorder market consists of revenues earned by entities by providing services such as rehabilitation services, patient assistance programs, and intravenous immunoglobulin (IVIG) therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuromyelitis optica spectrum disorder market includes sales of immunosuppressants, corticosteroids, and symptomatic treatments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Neuromyelitis Optica Spectrum Disorder Industry?

The neuromyelitis optica spectrum disorder market research report is one of a series of new reports from The Business Research Company that provides neuromyelitis optica spectrum disorder market statistics, including the neuromyelitis optica spectrum disorder industry global market size, regional shares, competitors with the neuromyelitis optica spectrum disorder market share, detailed neuromyelitis optica spectrum disorder market segments, market trends, and opportunities, and any further data you may need to thrive in the neuromyelitis optica spectrum disorder industry. This neuromyelitis optica spectrum disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Neuromyelitis Optica Spectrum Disorder Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$2.55 billion
Revenue Forecast In 2034	$3.52 billion
Growth Rate	CAGR of 8.4% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The neuromyelitis optica spectrum disorder market covered in this report is segmented – 1) By Type: Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies 2) By Diagnosis: Imaging Tests, Magnetic Resonance Imaging (MRI), Blood Tests, Others Diagnosis 3) By Treatment Type: C5 Protein Inhibitor, Monoclonal Antibodies, Plasma Exchange Therapy, Corticosteroids, Immunoglobulin Therapy, Medication, Other Treatment Types 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP 4) Antibodies: Relapsing NMOSD with AQP4-IgG, Monophasic NMOSD with AQP4-IgG, Severe Optic Neuritis with AQP4-IgG, Longitudinally Extensive Transverse Myelitis (LETM) with AQP4-IgG 2) By Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP 4) Antibodies: NMOSD with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG), Seronegative NMOSD, Idiopathic NMOSD Cases, NMOSD Associated With Other Autoimmune Disorders
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	F. Hoffmann-La Roche Ltd., AstraZeneca, Merck KGaA, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd., Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc., Oregon Health & Science University, Arup Laboratories, Argenx SE, TG Therapeutics Inc., RemeGen Co. Ltd., Metropolis Healthcare, IASO Biotherapeutics, Harbour BioMed, Rush University Medical Center, Bio-Thera Solutions Ltd., Mitsubishi Tanabe Pharma Corporation, Viela Bio, Opexa Therapeutics
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options
Market Size Value In 2025	$2.55 billion
Revenue Forecast In 2034	$3.52 billion
Growth Rate	CAGR of 8.4% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The neuromyelitis optica spectrum disorder market covered in this report is segmented – 1) By Type: Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies 2) By Diagnosis: Imaging Tests, Magnetic Resonance Imaging (MRI), Blood Tests, Others Diagnosis 3) By Treatment Type: C5 Protein Inhibitor, Monoclonal Antibodies, Plasma Exchange Therapy, Corticosteroids, Immunoglobulin Therapy, Medication, Other Treatment Types 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy 5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP 4) Antibodies: Relapsing NMOSD with AQP4-IgG, Monophasic NMOSD with AQP4-IgG, Severe Optic Neuritis with AQP4-IgG, Longitudinally Extensive Transverse Myelitis (LETM) with AQP4-IgG 2) By Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP 4) Antibodies: NMOSD with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG), Seronegative NMOSD, Idiopathic NMOSD Cases, NMOSD Associated With Other Autoimmune Disorders
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	F. Hoffmann-La Roche Ltd., AstraZeneca, Merck KGaA, Laboratory Corporation of America Holding, Chugai Pharmaceutical Co. Ltd., Mayo Foundation for Medical Education and Research, Penn Medicine, Genentech Inc., Oregon Health & Science University, Arup Laboratories, Argenx SE, TG Therapeutics Inc., RemeGen Co. Ltd., Metropolis Healthcare, IASO Biotherapeutics, Harbour BioMed, Rush University Medical Center, Bio-Thera Solutions Ltd., Mitsubishi Tanabe Pharma Corporation, Viela Bio, Opexa Therapeutics
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Neuromyelitis Optica Spectrum Disorder Market Characteristics

3. Neuromyelitis Optica Spectrum Disorder Market Trends And Strategies

4. Neuromyelitis Optica Spectrum Disorder Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neuromyelitis Optica Spectrum Disorder Growth Analysis And Strategic Analysis Framework

5.1. Global Neuromyelitis Optica Spectrum Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Neuromyelitis Optica Spectrum Disorder Market Growth Rate Analysis

5.4. Global Neuromyelitis Optica Spectrum Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Neuromyelitis Optica Spectrum Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Neuromyelitis Optica Spectrum Disorder Total Addressable Market (TAM)

6. Neuromyelitis Optica Spectrum Disorder Market Segmentation

6.1. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies

Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies

6.2. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Imaging Tests

Magnetic Resonance Imaging (MRI)

Blood Tests

Others Diagnosis

6.3. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

C5 Protein Inhibitor

Monoclonal Antibodies

Plasma Exchange Therapy

Corticosteroids

Immunoglobulin Therapy

Medication

Other Treatment Types

6.4. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

6.5. Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Specialty Clinics

Homecare

Other End-Users

6.6. Global Neuromyelitis Optica Spectrum Disorder Market, Sub-Segmentation Of Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP4) Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Relapsing NMOSD with AQP4-IgG

Monophasic NMOSD with AQP4-IgG

Severe Optic Neuritis with AQP4-IgG

Longitudinally Extensive Transverse Myelitis (LETM) with AQP4-IgG

6.7. Global Neuromyelitis Optica Spectrum Disorder Market, Sub-Segmentation Of Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP4) Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

NMOSD with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG)

Seronegative NMOSD

Idiopathic NMOSD Cases

NMOSD Associated With Other Autoimmune Disorders

7. Neuromyelitis Optica Spectrum Disorder Market Regional And Country Analysis

7.1. Global Neuromyelitis Optica Spectrum Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Neuromyelitis Optica Spectrum Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market

8.1. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neuromyelitis Optica Spectrum Disorder Market

9.1. China Neuromyelitis Optica Spectrum Disorder Market Overview

9.2. China Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neuromyelitis Optica Spectrum Disorder Market

10.1. India Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neuromyelitis Optica Spectrum Disorder Market

11.1. Japan Neuromyelitis Optica Spectrum Disorder Market Overview

11.2. Japan Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neuromyelitis Optica Spectrum Disorder Market

12.1. Australia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neuromyelitis Optica Spectrum Disorder Market

13.1. Indonesia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neuromyelitis Optica Spectrum Disorder Market

14.1. South Korea Neuromyelitis Optica Spectrum Disorder Market Overview

14.2. South Korea Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neuromyelitis Optica Spectrum Disorder Market

15.1. Western Europe Neuromyelitis Optica Spectrum Disorder Market Overview

15.2. Western Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neuromyelitis Optica Spectrum Disorder Market

16.1. UK Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neuromyelitis Optica Spectrum Disorder Market

17.1. Germany Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neuromyelitis Optica Spectrum Disorder Market

18.1. France Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neuromyelitis Optica Spectrum Disorder Market

19.1. Italy Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neuromyelitis Optica Spectrum Disorder Market

20.1. Spain Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market

21.1. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market Overview

21.2. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neuromyelitis Optica Spectrum Disorder Market

22.1. Russia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neuromyelitis Optica Spectrum Disorder Market

23.1. North America Neuromyelitis Optica Spectrum Disorder Market Overview

23.2. North America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neuromyelitis Optica Spectrum Disorder Market

24.1. USA Neuromyelitis Optica Spectrum Disorder Market Overview

24.2. USA Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neuromyelitis Optica Spectrum Disorder Market

25.1. Canada Neuromyelitis Optica Spectrum Disorder Market Overview

25.2. Canada Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neuromyelitis Optica Spectrum Disorder Market

26.1. South America Neuromyelitis Optica Spectrum Disorder Market Overview

26.2. South America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neuromyelitis Optica Spectrum Disorder Market

27.1. Brazil Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neuromyelitis Optica Spectrum Disorder Market

28.1. Middle East Neuromyelitis Optica Spectrum Disorder Market Overview

28.2. Middle East Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neuromyelitis Optica Spectrum Disorder Market

29.1. Africa Neuromyelitis Optica Spectrum Disorder Market Overview

29.2. Africa Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neuromyelitis Optica Spectrum Disorder Market Competitive Landscape And Company Profiles

30.1. Neuromyelitis Optica Spectrum Disorder Market Competitive Landscape

30.2. Neuromyelitis Optica Spectrum Disorder Market Company Profiles

30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. AstraZeneca Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Laboratory Corporation of America Holding Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Neuromyelitis Optica Spectrum Disorder Market Other Major And Innovative Companies

31.1. Mayo Foundation for Medical Education and Research

31.2. Penn Medicine

31.3. Genentech Inc.

31.4. Oregon Health & Science University

31.5. Arup Laboratories

31.6. Argenx SE

31.7. TG Therapeutics Inc.

31.8. RemeGen Co. Ltd.

31.9. Metropolis Healthcare

31.10. IASO Biotherapeutics

31.11. Harbour BioMed

31.12. Rush University Medical Center

31.13. Bio-Thera Solutions Ltd.

31.14. Mitsubishi Tanabe Pharma Corporation

31.15. Viela Bio

32. Global Neuromyelitis Optica Spectrum Disorder Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neuromyelitis Optica Spectrum Disorder Market

34. Recent Developments In The Neuromyelitis Optica Spectrum Disorder Market

35. Neuromyelitis Optica Spectrum Disorder Market High Potential Countries, Segments and Strategies

35.1 Neuromyelitis Optica Spectrum Disorder Market In 2029 - Countries Offering Most New Opportunities

35.2 Neuromyelitis Optica Spectrum Disorder Market In 2029 - Segments Offering Most New Opportunities

35.3 Neuromyelitis Optica Spectrum Disorder Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Neuromyelitis Optica Spectrum Disorder Market, Sub-Segmentation Of Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP4) Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Neuromyelitis Optica Spectrum Disorder Market, Sub-Segmentation Of Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP4) Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Neuromyelitis Optica Spectrum Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Neuromyelitis Optica Spectrum Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Asia-Pacific, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: China, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: India, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Japan, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Australia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Indonesia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: South Korea, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: Western Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: UK, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: Germany, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: France, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Italy, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Spain, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Eastern Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Russia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: North America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: USA, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: Canada, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: South America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Brazil, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Middle East, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Africa, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: F. Hoffmann-La Roche Ltd. Financial Performance

Table 79: AstraZeneca Financial Performance

Table 80: Merck KGaA Financial Performance

Table 81: Laboratory Corporation of America Holding Financial Performance

Table 82: Chugai Pharmaceutical Co. Ltd. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Neuromyelitis Optica Spectrum Disorder Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Neuromyelitis Optica Spectrum Disorder Market, Sub-Segmentation Of Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP4) Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Neuromyelitis Optica Spectrum Disorder Market, Sub-Segmentation Of Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP4) Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Neuromyelitis Optica Spectrum Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Neuromyelitis Optica Spectrum Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Asia-Pacific, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: China, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: India, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Japan, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Australia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Indonesia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: South Korea, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: Western Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: UK, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: Germany, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: France, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Italy, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Spain, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Eastern Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Russia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: North America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: USA, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: Canada, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: South America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Brazil, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Middle East, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Africa, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Neuromyelitis Optica Spectrum Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 79: AstraZeneca Financial Performance

Figure 80: Merck KGaA Financial Performance

Figure 81: Laboratory Corporation of America Holding Financial Performance

Figure 82: Chugai Pharmaceutical Co. Ltd. Financial Performance

The Business Research Company offers the rcm market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the video management system market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the single use bioprocessing market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the consumer healthcare market research report 2022 with industry size, share, segments and market growth

Global Mycoplasma Testing Market 2022 – Market Opportunities And Strategies

Latest Hospice Care Market Growth Study 2022-2026 By The Business Research Company

The Healthcare Education Market Share, Market Size, And Growth Rate 2022

Global Healthcare Distribution Market 2022 – Market Opportunities And Strategies

Microdisplay Global Market Report 2025 – By Product (Near-To-Eye (NTE) Devices, Head-Up Displays (HUDs), Projectors, Other Products), By Brightness (Less Than 500 Nits, 500–1,000 Nits, More Than 1,000 Nits), By Resolution (Lower Than HD (High Definition), HD (High Definition), FHD (Full High Definition), Higher Than FHD (Full High Definition)), By Technology (Liquid Crystal Display (LCD), Liquid Crystal On Silicon (LCOD), Organic Light-Emitting Diode (OLED), Digital Light Processing (DLP)), By Vertical (Consumer, Automotive, Industrial And Enterprise, Military, Defense, And Aerospace, Retail And Hospitality, Medical, Education, Sports And Entertainment, Other Verticals) – Market Size, Trends, And Global Forecast 2025-2034

View Report

3D Laser Scanner Global Market Report 2025 – By Product (Tripod Mounted, Fixed Coordinate Measuring Machine Based, Portable Coordinate Measuring Machine Based, Desktop), By Range (Short, Medium, Long), By Offerings (Hardware And Software, After-Sales Services), By Application (Quality Control And Inspection, Reverse Engineering, Virtual Simulation, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Agricultural Biologics Global Market Report 2025 – By Type (Biopesticides, Biofertilizers, Biostimulants), By Source (Microbials, Macrobials, Biochemicals, Other Sources), By Mode of Application (Foliar Spray, Soil Treatment, Seed Treatment, Post-Harvest), By Application (Cereals And Grains, Oilseed And Pulses, Fruits And Vegetables, Turf And Ornamentals, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Animal Based Protein Supplements Global Market Report 2025 – By Product (Protein Powder, Protein Bars, Ready-To-Drink, Other Products), By Raw Materials (Whey, Casein, Egg, Fish, Other Raw Materials), By Application (Pharmaceuticals and Nutraceuticals, Food and Beverages, Infant Formulations, Cosmetics and Personal Care, Animal Feed, And Dietary Supplements), By Distribution Channel (Supermarkets And Hypermarkets, Online Stores, Chemists or Drugstores, Specialty Stores, Other Distribution Channels) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Digital Health Monitoring Devices Global Market Report 2025 – By Type( Tele-health, EHR/EMR, M-health, Wireless health, Remote Patient Monitoring ), By Product type( Device, Software, Services, Other Products), By End User( Hospitals, Clinics, Ambulatory surgical centers, Homecare settings, Other End-users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

End Stage Renal Disease (ESRD) Drug Global Market Report 2025 – By Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products), By Indication (End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Printed Circuit Board Market 2023 – By Type (Single Sided, Double Sided, Multi-Layer, High Density Interconnect (HDI), Other Types), By Substrate (Rigid, Flexible, Rigid-Flex), By Laminate Type (FR-4, Polyimide, Other Laminate Types), By End-Use Industry (Industrial Electronics, Healthcare, Aerospace And Defense, Automotive, IT And Telecom, Consumer Electronics, Other End Users), And By Region, Opportunities And Strategies – Global Forecast To 2032

View Report

Frequently Asked Questions

What is the definition of the Neuromyelitis Optica Spectrum Disorder market?

How will the Neuromyelitis Optica Spectrum Disorder market drivers and restraints affect the market dynamics? What forces will shape the Neuromyelitis Optica Spectrum Disorder industry going forward?

The Neuromyelitis Optica Spectrum Disorder market major growth driver - Rising Multiple Sclerosis Cases Fueling The Growth Of The Market Due To Improved Diagnostics And Increased Awareness. For further insights on the Neuromyelitis Optica Spectrum Disorder market, request a sample here

What is the forecast market size or the forecast market value of the Neuromyelitis Optica Spectrum Disorder market?

The Neuromyelitis Optica Spectrum Disorder market size has grown strongly in recent years. The neuromyelitis optica spectrum disorder market size has grown strongly in recent years. It will grow from $2.35 billion in 2024 to $2.55 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the increasing prevalence of Neuromyelitis Optica Spectrum Disorder (NMOSD), rising awareness and early diagnosis, rising therapeutic options and FDA approvals, growing research and development activities, and rising clinical trials for novel therapies. The neuromyelitis optica spectrum disorder market size is expected to see strong growth in the next few years. It will grow to $3.52 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising awareness and early diagnosis, increasing healthcare expenditure, rising investments in research and development, increasing prevalence of autoimmune diseases, increasing clinical trials for NMOSD therapies, and growing demand for personalized medicine. Major trends in the forecast period include advancements in precision medicine, collaboration & partnerships, technological innovations, integration of AI & big data in research, and a shift towards home-based treatments. For further insights on the Neuromyelitis Optica Spectrum Disorder market, request a sample here

How is the Neuromyelitis Optica Spectrum Disorder market segmented?

The Neuromyelitis Optica Spectrum Disorder market covered in this report is segmented –
1) By Type: Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies; Neuromyelitis Optica Spectrum Disorder Without Aquaporin-4 Antibodies
2) By Diagnosis: Imaging Tests; Magnetic Resonance Imaging (MRI); Blood Tests; Others Diagnosis
3) By Treatment Type: C5 Protein Inhibitor; Monoclonal Antibodies; Plasma Exchange Therapy; Corticosteroids; Immunoglobulin Therapy; Medication; Other Treatment Types
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

Subsegments:
1) By Neuromyelitis Optica Spectrum Disorder (NMOSD) With Aquaporin-4 (AQP4) Antibodies: Relapsing NMOSD with AQP4-IgG; Monophasic NMOSD with AQP4-IgG; Severe Optic Neuritis with AQP4-IgG; Longitudinally Extensive Transverse Myelitis (LETM) with AQP4-IgG
2) By Neuromyelitis Optica Spectrum Disorder (NMOSD) Without Aquaporin-4 (AQP4) Antibodies: NMOSD with Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies (MOG-IgG); Seronegative NMOSD; Idiopathic NMOSD Cases; NMOSD Associated With Other Autoimmune Disorders For further insights on the Neuromyelitis Optica Spectrum Disorder market, request a sample here

Which region has the largest share of the Neuromyelitis Optica Spectrum Disorder market? What are the other regions covered in the report?

Who are the major players in the Neuromyelitis Optica Spectrum Disorder market?

What are the key trends in the Neuromyelitis Optica Spectrum Disorder market?

Major trends in the Neuromyelitis Optica Spectrum Disorder market include Advancements In Complement Inhibition Transform NMOSD Treatment Landscape. For further insights on the Neuromyelitis Optica Spectrum Disorder market, request a sample here.

What are the major opportunities in the Neuromyelitis Optica Spectrum Disorder market? What are the strategies for the Neuromyelitis Optica Spectrum Disorder market?

For detailed insights on the major opportunities and strategies in the Neuromyelitis Optica Spectrum Disorder market, request a sample here.

How does the Neuromyelitis Optica Spectrum Disorder market relate to the overall economy and other similar markets?

For detailed insights on Neuromyelitis Optica Spectrum Disorder's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Neuromyelitis Optica Spectrum Disorder industry?

For detailed insights on the mergers and acquisitions in the Neuromyelitis Optica Spectrum Disorder industry, request a sample here.

What are the key dynamics influencing the Neuromyelitis Optica Spectrum Disorder market growth? SWOT analysis of the Neuromyelitis Optica Spectrum Disorder market.

For detailed insights on the key dynamics influencing the Neuromyelitis Optica Spectrum Disorder market growth and SWOT analysis of the Neuromyelitis Optica Spectrum Disorder industry, request a sample here.